Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALTABA INC.YHOO · Entity 13268 | Director | June 13, 2017 | June 15, 2017 |
| Innoviva, Inc.INVA · Entity 4679 | Director | April 20, 2017 | April 24, 2017 |
| Lyell Immunopharma, Inc.LYEL · Entity 5757 | Director | June 10, 2026 | June 12, 2026 |
| Revolution Healthcare Acquisition Corp.REVH · Entity 135631 | Director | March 17, 2021 | March 17, 2021 |
| Seer, Inc.SEER · Entity 6717 | Director | June 14, 2023 | June 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALTABA INC.
Report date June 13, 2017 · Filed June 15, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-06-13 transaction · row 1
1 source rowRow 1 · 2017-06-13 · Disposition to issuer · Disposed 8,545 · Balance 0 F1: Represents amendment of the Reporting Person's outstanding restricted stock unit awards (the acquisition of which was previously reported in Table I of Form 4) under the issuer's Directors' Stock Plan, changing the awards' terms from stock-settlement to cash-settlement. |
| Cash-Settled Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2020-09-01 | Direct | 8,545 |
Reported balance
After 2017-06-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-06-13 · Grant · Acquired 8,545 · Balance 8,545 F2: Each cash-settled restricted stock unit is the economic equivalent of one share of Altaba Inc. common stock. F1: Represents amendment of the Reporting Person's outstanding restricted stock unit awards (the acquisition of which was previously reported in Table I of Form 4) under the issuer's Directors' Stock Plan, changing the awards' terms from stock-settlement to cash-settlement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents amendment of the Reporting Person's outstanding restricted stock unit awards (the acquisition of which was previously reported in Table I of Form 4) under the issuer's Directors' Stock Plan, changing the awards' terms from stock-settlement to cash-settlement.
F2: Each cash-settled restricted stock unit is the economic equivalent of one share of Altaba Inc. common stock.
Innoviva, Inc.
Report date April 20, 2017 · Filed April 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 73,805 |
Reported balance
After 2017-04-20 transaction · row 1
1 source rowRow 1 · 2017-04-20 · Grant · Acquired 19,857 · Balance 73,805 F1: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual shareholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual shareholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date.
Lyell Immunopharma, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.22 · Expires 2036-06-09 | Direct | 9,250 |
Reported balance
After 2026-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-10 · Grant · Acquired 9,250 · Balance 9,250 F4: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date. |
| Common StockSEC Table I · non-derivative | IndirectMSL FBO J DUANE & C FRIEDMAN TTEE DUANE FAMILY TRUST | 11,818 |
Reported balance
Holding disclosure · report date 2026-06-10 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 11,818 F1: On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split. F2: The Reporting Person is a trustee of MSL FBO J DUANE & C FRIEDMAN TTEE DUANE FAMILY TRUST ("Duane Family Trust") and therefore may be deemed to share the power to direct the disposition and vote of the shares held by the Duane Family Trust. The Reporting Person disclaims beneficial ownership of all shares held by Duane Family Trust except to any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectThe Duane Irrevocable Trust 2020 | 5,000 |
Reported balance
Holding disclosure · report date 2026-06-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,000 F1: On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split. F3: The Reporting Person is a trustee of The Duane Irrevocable Trust 2020 ("Duane Irrevocable Trust") and therefore may be deemed to share the power to direct the disposition and vote of the shares held by the Duane Irrevocable Trust. The Reporting Person disclaims beneficial ownership of all shares held by Duane Irrevocable Trust except to any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split.
F2: The Reporting Person is a trustee of MSL FBO J DUANE & C FRIEDMAN TTEE DUANE FAMILY TRUST ("Duane Family Trust") and therefore may be deemed to share the power to direct the disposition and vote of the shares held by the Duane Family Trust. The Reporting Person disclaims beneficial ownership of all shares held by Duane Family Trust except to any pecuniary interest therein.
F3: The Reporting Person is a trustee of The Duane Irrevocable Trust 2020 ("Duane Irrevocable Trust") and therefore may be deemed to share the power to direct the disposition and vote of the shares held by the Duane Irrevocable Trust. The Reporting Person disclaims beneficial ownership of all shares held by Duane Irrevocable Trust except to any pecuniary interest therein.
F4: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.
Revolution Healthcare Acquisition Corp.
Report date March 17, 2021 · Filed March 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B common stockSEC Table I · non-derivative | Direct | 6,250 |
Reported balance
Holding disclosure · report date 2021-03-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 6,250 F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-253729), as amended, under the heading "Description of Securities - Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the Issuer after the consummation of the Issuer's initial business combination. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-253729), as amended, under the heading "Description of Securities - Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the Issuer after the consummation of the Issuer's initial business combination.
Seer, Inc.
Report date June 14, 2023 · Filed June 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 173,574 |
Reported balance
After 2023-06-14 transaction · row 1
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 23,443 · Balance 173,574 F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 14, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.33 · Expires 2033-06-14 | Direct | 34,735 |
Reported balance
After 2023-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-14 · Grant · Acquired 34,735 · Balance 34,735 F2: Shares subject to the option vest on the earlier of (i) June 14, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 14, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.
F2: Shares subject to the option vest on the earlier of (i) June 14, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Radius Health, Inc.
Report date August 15, 2022 · Filed August 15, 2022
Section 16 reporting ended · disclosed 2022-08-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-08-15 transaction · row 1
1 source rowRow 1 · 2022-08-15 · Disposition to issuer · Disposed 26,800 · Balance 0 F1: Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.40 · Expires 2032-01-14 | Direct | 0 |
Reported balance
After 2022-08-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-15 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, these options automatically vested and were cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (without interest) (A) an amount in cash (less applicable Tax withholdings) equal to the product of (x) the total number of Shares subject to such option immediately prior to the effective time multiplied by (y) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option, and (B) one CVR for each Share subject thereto. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share.
F2: Pursuant to the Merger Agreement, at the Effective Time, these options automatically vested and were cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (without interest) (A) an amount in cash (less applicable Tax withholdings) equal to the product of (x) the total number of Shares subject to such option immediately prior to the effective time multiplied by (y) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option, and (B) one CVR for each Share subject thereto.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 20:19 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 9,250 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001411874-26-000002 · form4-06122026_080616.xml · derivative · entry 3 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,250 Underlying: Common Stock · 9,250 shares Expires 2036-06-09 F4 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:47 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 130,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001415889-25-013712 · form4-05192025_100556.xml · derivative · entry 3 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2035-05-14 F3 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following May 15, 2025 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of May 15, 2025, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:05 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 130,000 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001415889-24-017146 · form4-06172024_080617.xml · derivative · entry 3 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2034-06-13 F3 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 14, 2024 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 14, 2024, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| September 08, 2023 Filed Sep 8, 2023 20:26 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 55,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001209191-23-048785 · doc4.xml · derivative · entry 3 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2033-09-07 F3 · security: On September 6, 2023, to align with benchmarking data, the issuer's Compensation Committee amended the Non-Employee Director Compensation Policy to increase the annual equity grant to non-employee directors. The Reporting Person was granted an option to purchase 65,000 shares on June 16, 2023, prior to the amendment of the policy. This additional option grant aligns the Reporting Person's total 2023 grants with the updated policy. F4 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 16, 2023 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be re-elected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 16, 2023, subject to the Reporting Person providing continuous service through such date Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 20:43 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 65,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001209191-23-038437 · doc4.xml · derivative · entry 3 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2033-06-15 F3 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 16, 2023 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 16, 2023, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| June 14, 2023 Filed Jun 17, 2023 01:15 UTC | Seer, Inc. SEER · Entity 6717 | GrantStock Option (right to buy) · Derivative | 34,735 | $0.00 Strike: $4.33 | $0.00 |
DisclosureSEC source: 0001209191-23-038186 · doc4.xml · derivative · entry 2 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,735 Underlying: Class A Common Stock · 34,735 shares Expires 2033-06-14 F2 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 14, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 14, 2023 Filed Jun 17, 2023 01:15 UTC | Seer, Inc. SEER · Entity 6717 | GrantClass A Common Stock | 23,443 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038186 · doc4.xml · nonDerivative · entry 1 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,574 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 14, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| August 15, 2022 Filed Aug 15, 2022 16:17 UTC | Radius Health, Inc. RDUS · Entity 124173 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | $3.60 Strike: $6.40 | $36,000.00 |
DisclosureSEC source: 0000899243-22-028642 · doc4.xml · derivative · entry 2 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2032-01-14 F2 · price: Pursuant to the Merger Agreement, at the Effective Time, these options automatically vested and were cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (without interest) (A) an amount in cash (less applicable Tax withholdings) equal to the product of (x) the total number of Shares subject to such option immediately prior to the effective time multiplied by (y) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option, and (B) one CVR for each Share subject thereto. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, these options automatically vested and were cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (without interest) (A) an amount in cash (less applicable Tax withholdings) equal to the product of (x) the total number of Shares subject to such option immediately prior to the effective time multiplied by (y) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option, and (B) one CVR for each Share subject thereto. Read SEC document |
| August 15, 2022 Filed Aug 15, 2022 16:17 UTC | Radius Health, Inc. RDUS · Entity 124173 | Disposition to issuerCommon Stock | 26,800 | $10.00 | $268,000.00 |
DisclosureSEC source: 0000899243-22-028642 · doc4.xml · nonDerivative · entry 1 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share. F1 · price: Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 22:28 UTC | Seer, Inc. SEER · Entity 6717 | GrantStock Option (right to buy) · Derivative | 29,640 | $0.00 Strike: $7.33 | $0.00 |
DisclosureSEC source: 0001209191-22-038080 · doc4.xml · derivative · entry 2 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,640 Underlying: Class A Common Stock · 29,640 shares Expires 2031-06-15 F2 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 15, 2023 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 22:28 UTC | Seer, Inc. SEER · Entity 6717 | GrantClass A Common Stock | 9,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038080 · doc4.xml · nonDerivative · entry 1 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,131 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 15, 2023 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:09 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 65,000 | $0.00 Strike: $5.31 | $0.00 |
DisclosureSEC source: 0001209191-22-035837 · doc4.xml · derivative · entry 3 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2032-06-07 F3 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 8, 2022 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 8, 2022, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| January 14, 2022 Filed Jan 25, 2022 16:30 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.40 | $0.00 |
DisclosureSEC source: 0001209191-22-004785 · doc4.xml · derivative · entry 2 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-01-14 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the grant date, subject to continued service with RDUS through such date. Read SEC document |
| January 14, 2022 Filed Jan 25, 2022 16:30 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantCommon Stock | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-004785 · doc4.xml · nonDerivative · entry 1 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,800 F1 · price: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in full on the first anniversary of the award date, subject to continued service with RDUS through such date. Read SEC document |
| December 14, 2021 Filed Dec 14, 2021 21:57 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | OtherCommon Stock | 218,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069485 · doc4.xml · nonDerivative · entry 2 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · MSL FBO J DUANE & C FRIEDMAN TTEE DUANE FAMILY TRUST Disclosed balance after: 236,370 F2 · ownership.nature: Received in a pro-rata distribution from Lyell Investors, LLC. The Reporting Person is a trustee of MSL FBO J DUANE & C FRIEDMAN TTEE DUANE FAMILY TRUST ("Duane Family Trust") and therefore may be deemed to share the power to direct the disposition and vote of the shares held by the Duane Family Trust. The Reporting Person disclaims beneficial ownership of all shares held by Duane Family Trust except to any pecuniary interest therein. Read SEC document |
| December 14, 2021 Filed Dec 14, 2021 21:57 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | OtherCommon Stock | 3,765,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069485 · doc4.xml · nonDerivative · entry 1 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Lyell Investors, LLC Disclosed balance after: 0 F1 · ownership.nature: Pro-rata distribution by Lyell Investors, LLC to its members. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 21:33 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | ConversionSeries A Convertible Preferred Stock · Derivative | 3,765,842 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-042795 · doc4.xml · derivative · entry 4 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Lyell Investors, LLC Disclosed balance after: 0 Underlying: Common Stock · 3,765,842 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's Series A Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date. F1 · price: The Issuer's Series A Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date. F1 · derivative.exercise_date: The Issuer's Series A Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date. F1 · derivative.expiration_date: The Issuer's Series A Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date. F2 · ownership.nature: The Reporting Person is a member of Lyell Investors, LLC and therefore may be deemed to share the power to direct the disposition and vote of the shares held by Lyell Investors, LLC. The Reporting Person disclaims beneficial ownership of all shares held by Lyell Investors, LLC except to any pecuniary interest therein. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 21:33 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | PurchaseCommon Stock | 17,648 | $17.00 | $300,016.00 |
DisclosureSEC source: 0001209191-21-042795 · doc4.xml · nonDerivative · entry 2 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · MSL FBO J DUANE & C FRIEDMAN TTEE DUANE FAMILY TRUST Disclosed balance after: 17,648 F3 · ownership.nature: The Reporting Person is a trustee of MSL FBO J DUANE & C FRIEDMAN TTEE DUANE FAMILY TRUST ("Duane Family Trust") and therefore may be deemed to share the power to direct the disposition and vote of the shares held by the Duane Family Trust. The Reporting Person disclaims beneficial ownership of all shares held by Duane Family Trust except to any pecuniary interest therein. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 21:33 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | ConversionCommon Stock | 3,765,842 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-042795 · doc4.xml · nonDerivative · entry 1 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Lyell Investors, LLC Disclosed balance after: 3,765,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's Series A Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date. F2 · ownership.nature: The Reporting Person is a member of Lyell Investors, LLC and therefore may be deemed to share the power to direct the disposition and vote of the shares held by Lyell Investors, LLC. The Reporting Person disclaims beneficial ownership of all shares held by Lyell Investors, LLC except to any pecuniary interest therein. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 22:23 UTC | Seer, Inc. SEER · Entity 6717 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $33.74 | $0.00 |
DisclosureSEC source: 0001209191-21-042500 · doc4.xml · derivative · entry 1 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 17, 2022 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 17:48 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $18.60 | $0.00 |
DisclosureSEC source: 0001209191-21-013332 · doc4.xml · derivative · entry 2 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-02-22 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the grant date, subject to continued service with RDUS through such date. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 17:48 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantCommon Stock | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-013332 · doc4.xml · nonDerivative · entry 1 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,300 F1 · price: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in full on the first anniversary of the award date, subject to continued service with RDUS through such date. Read SEC document |
| January 21, 2021 Filed Jan 25, 2021 17:04 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001209191-21-005111 · doc4.xml · derivative · entry 1 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-01-21 F1 · derivative.exercise_date: This option shall vest in full on the first anniversary of the grant date or upon an earlier Change of Control (as defined in the registrant's 2018 Stock Option and Incentive Plan). Read SEC document |
| December 03, 2020 Filed Dec 12, 2020 02:10 UTC | Seer, Inc. SEER · Entity 6717 | GrantStock Option (right to buy) · Derivative | 18,691 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001628280-20-017428 · wf-form4_160773903250913.xml · derivative · entry 1 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,691 Underlying: Class A Common Stock · 18,691 shares Expires 2020-12-03 F1 · derivative.exercise_date: Shares subject to the option vest in 36 equal monthly installments beginning on January 3, 2021. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 18:28 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.96 | $0.00 |
DisclosureSEC source: 0001209191-20-012186 · doc4.xml · derivative · entry 2 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-02-20 F2 · derivative.exercise_date: The option vests in full on February 20, 2021, subject to continued service with RDUS through such date. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 18:28 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantCommon Stock | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-012186 · doc4.xml · nonDerivative · entry 1 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,800 F1 · price: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in full on February 20, 2021, subject to continued service with RDUS through such date. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 18:13 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.18 | $0.00 |
DisclosureSEC source: 0001209191-19-013699 · doc4.xml · derivative · entry 2 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-02-22 F2 · derivative.exercise_date: The option vests in full on February 22, 2020, subject to continued service with RDUS through such date. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 18:13 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantCommon Stock | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-013699 · doc4.xml · nonDerivative · entry 1 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,300 F1 · price: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in full on February 22, 2020, subject to continued service with RDUS through such date. Read SEC document |
| February 13, 2019 Filed Feb 13, 2019 17:16 UTC | Radius Health, Inc. RDUS · Entity 124173 | Exercise / conversionRestricted Stock Units · Derivative | 4,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-009734 · doc4.xml · derivative · entry 2 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on February 13, 2019. F2 · derivative.expiration_date: The restricted stock units vested in full on February 13, 2019. Read SEC document |
| February 13, 2019 Filed Feb 13, 2019 17:16 UTC | Radius Health, Inc. RDUS · Entity 124173 | Exercise / conversionCommon Stock | 4,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-009734 · doc4.xml · nonDerivative · entry 1 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 19:37 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantRestricted Stock Units · Derivative | 4,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-010544 · doc4.xml · derivative · entry 2 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800 Underlying: Common Stock · 4,800 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. F3 · derivative.exercise_date: The restricted stock units shall vest in full on February 13, 2019. F3 · derivative.expiration_date: The restricted stock units shall vest in full on February 13, 2019. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 19:37 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 8,800 | $0.00 Strike: $37.83 | $0.00 |
DisclosureSEC source: 0001209191-18-010544 · doc4.xml · derivative · entry 1 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,800 Underlying: Common Stock · 8,800 shares Expires 2028-02-12 F1 · derivative.exercise_date: The option vests in full on February 13, 2019, subject to continued service to the Issuer through such date. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 19:39 UTC | ALTABA INC. YHOO · Entity 13268 | GrantCash-Settled Restricted Stock Units · Derivative | 8,545 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001127602-17-021498 · form4.xml · derivative · entry 2 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,545 Underlying: Common Stock · 8,545 shares Expires 2020-09-01 F2 · derivative.exercise_price: Each cash-settled restricted stock unit is the economic equivalent of one share of Altaba Inc. common stock. F1 · price: Represents amendment of the Reporting Person's outstanding restricted stock unit awards (the acquisition of which was previously reported in Table I of Form 4) under the issuer's Directors' Stock Plan, changing the awards' terms from stock-settlement to cash-settlement. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 19:39 UTC | ALTABA INC. YHOO · Entity 13268 | Disposition to issuerCommon Stock | 8,545 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-021498 · form4.xml · nonDerivative · entry 1 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Represents amendment of the Reporting Person's outstanding restricted stock unit awards (the acquisition of which was previously reported in Table I of Form 4) under the issuer's Directors' Stock Plan, changing the awards' terms from stock-settlement to cash-settlement. Read SEC document |
| April 20, 2017 Filed Apr 24, 2017 21:24 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 19,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-006175 · edgar.xml · nonDerivative · entry 1 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,805 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual shareholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 16:24 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 27,500 | $0.00 Strike: $45.65 | $0.00 |
DisclosureSEC source: 0001209191-17-013241 · doc4.xml · derivative · entry 1 FRIEDMAN CATHY · CIK 0001411874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2027-02-16 F1 · derivative.exercise_date: The option vests in full on February 17, 2018, subject to continued service to the Issuer through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.